Effects of Prior Induced Termination of Pregnancy on Complications and Pregnancy Outcomes.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jiang Xue, M.D.
- Phone Number: +86 18011490663
- Email: jiangxue012800@163.com
Study Locations
-
-
-
Chongqing, China
- Recruiting
- Chongqing Health Center for Women and Children
-
Shenzhen, China
- Recruiting
- Shenzhen Luohu Maternity and Child Healthcare Hospital
-
-
Guangdong
-
Zhongshan, Guangdong, China
- Recruiting
- Zhongshan Boai Hospital
-
-
Hebei
-
Zhangjiakou, Hebei, China
- Recruiting
- Zhangjiakou Maternal and Child Health Hospital
-
Contact:
- Tu Pengcheng, M.D.
-
-
Heilongjiang
-
Daqing, Heilongjiang, China, 150000-160000
- Recruiting
- Daqing People's Hospital
-
Contact:
- Tu Pengcheng, M.D.
-
-
Jiangsu
-
Changzhou, Jiangsu, China
- Recruiting
- Changzhou Maternal and Child Health Hospital
-
Yangzhou, Jiangsu, China
- Recruiting
- Yangzhou Maternal and Child Health Hospital
-
-
Mongolia Autonomous
-
Hohhot, Mongolia Autonomous, China
- Recruiting
- People's Hospital of Inner Mongolia Autonomous Region
-
Contact:
- Tu Pengcheng, M.D.
-
-
Shandong
-
Qingdao, Shandong, China
- Completed
- Qingdao Maternal and Child Health Hospital
-
Zaozhuang, Shandong, China
- Recruiting
- Zaozhuang Maternal and Child Health Hospital
-
-
Shanxi
-
Taiyuan, Shanxi, China
- Recruiting
- Taiyuan Maternal and Child Health Hospital
-
-
Tianjin Municipality
-
Tanggu, Tianjin Municipality, China
- Completed
- Tanggu Maternal and Child Health Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- women have induced abortion in early pregnancy (<12 weeks of gestation).
- permanent population and no tendency to move.
- normal language expression and understanding ability, able to understand research content.
- be able and willing to provide written informed consent and effective contact information, and be willing to cooperate with follow-up investigations.
Exclusion Criteria:
- above the age of 40
- with history of adverse pregnancy and childbirth
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
adverse pregnancy outcomes
Time Frame: 2028.6
|
the rate of different adverse pregnancy outcomes
|
2028.6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complications
Time Frame: 2020.6
|
the rate of different complications
|
2020.6
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Pei Kaiyan, National Research Institute for Family Planning (NRIFP)
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- No.2018-I2M-1-004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.